Executive Summary
Contemporary balloon-expandable TAVR delivered equivalent 5-year mortality in bicuspid versus tricuspid anatomy across 515 propensity-matched pairs (13.2% vs 13.7%), the longest comparative BAV dataset to date and a direct challenge to guideline reluctance on transcatheter treatment of bicuspid disease (JACC: Cardiovascular Interventions). Separately, Medicare data on 400,862 TAVRs show surgical bailout has fallen to 0.40% but still carries 26.3% 30-day mortality — the strongest empirical argument yet against dismantling on-site surgical backup (JACC: Cardiovascular Interventions). CMS also expanded TAVR reimbursement coverage, moving Edwards' addressable Medicare pool wider (Citeline) — which tightens the case for TAVR volume growth while sharpening the debate over where those procedures should be performed.
- Portico self-expanding intra-annular valve matched commercial TAVR platforms at 5 years for death/stroke but drove pacemaker rates to 36.6% vs 20.3% (PORTICO IDE, JACC: Cardiovascular Interventions).
- SGLT2 inhibitor use before M-TEER cut all-cause mortality at 1 year (HR 0.76) in 2,814 propensity-matched patients, though the composite endpoint was neutral (CCI).
- Horizontal aorta (>60°) tripled subclinical cerebral infarction burden after self-expanding TAVR in 411 patients, a signal that anatomy still constrains transcatheter safety (J Clin Med).
- Transaxillary TAVR halved VARC-3 bleeding versus transfemoral (8.0% vs 22.0%) with equivalent mortality in 150 matched patients (Diagnostics).
- Medtronic's Intrepid TMVR pivotal trial updated enrollment to 1,056 patients, keeping it the largest active TMVR study (NCT03242642).
What to watch: Edwards' Q3 earnings on October 29 will be the first read on whether the CMS coverage expansion translates to sequential TAVR volume acceleration.
Aortic Valve (TAVR/TAVI)
The bicuspid TAVR data got longer legs today. A single-center propensity-matched analysis of 515 pairs treated with contemporary balloon-expandable valves found no difference in 5-year all-cause mortality (13.2% vs 13.7%), heart failure rehospitalization, stroke, or reintervention between bicuspid and tricuspid anatomy, with comparable ascending aortic growth rates (0.37 vs 0.31 mm/y) (JACC: Cardiovascular Interventions). [NOTABLE] This is single-center and non-randomized — real limitations — but it is the longest BAV TAVR follow-up published. The accompanying editorial questions whether tricuspid TAVR is even the right comparator for BAV (Van Belle et al.). Both ACC/AHA 2020 and ESC 2025 keep TAVR for BAV at Class IIb, largely because NOTION-2 showed a numerical event excess and RCTs have excluded these patients. Today's data don't change guideline status but narrow the empirical gap. SAVR remains preferred for young BAV patients with aortopathy or unfavorable morphology.
The 5-year PORTICO IDE update showed the self-expanding intra-annular valve matched commercial TAVR platforms for all-cause mortality/stroke (55.6% vs 51.3%) but with a striking pacemaker burden — 36.6% vs 20.3% — and numerically higher cardiovascular mortality (33.4% vs 25.8%, P=0.06) (JACC: Cardiovascular Interventions). A one-in-three pacemaker rate at 5 years is a durability and quality-of-life problem, particularly as TAVR indications expand to younger patients under ESC 2025's age-70 threshold.
Horizontal aorta (>60°), present in 16.8% of a 411-patient self-expanding TAVR cohort, independently predicted greater DW-MRI cerebral infarction burden — more lesions, larger volumes — though clinical stroke rates were similar (J Clin Med). Transaxillary access cut VARC-3 bleeding to 8.0% vs 22.0% transfemoral in a 150-patient matched cohort, with equivalent 30-day and 1-year mortality (Diagnostics). A phenotyping study of 1,212 TAVR patients identified a cardiorenal cluster with 3.4-fold mortality driven by non-cardiovascular causes, and derived a TAVR-RECOVER score stratifying LVEF recovery from 69% to 98% (Int J Cardiol Heart Vasc).
Mitral Valve (MitraClip, PASCAL, TMVR)
SGLT2 inhibitors keep expanding their footprint. A TriNetX analysis of 2,814 propensity-matched M-TEER patients found baseline SGLT2i use cut 1-year all-cause mortality (HR 0.76, P=0.004) and all-cause hospitalization (HR 0.83, P<0.001), though the composite of stroke/mortality/acute HF was neutral (CCI). Observational, subject to residual confounding — but consistent with a parallel 7,526-pair cardiac surgery cohort showing 30-day mortality of 1.3% vs 2.3% with preoperative SGLT2i (J Clin Med). Both point to an underused therapy in structural heart populations.
A pooled analysis of Carillon percutaneous annuloplasty in 113 FMR patients found higher baseline LV volumes predicted greater reverse remodeling, with distinct response patterns in proportionate vs disproportionate FMR (J Clin Med). This adds nuance to the COAPT/MITRA-FR/RESHAPE-HF2 framework that drove ESC 2025 to upgrade TEER to Class I for ventricular SMR — but Carillon is a different device with a smaller evidence base than TEER, and ACC/AHA 2020 still holds TEER for SMR at Class IIa. Surgical MV repair remains Class I for primary MR in symptomatic patients, and ESC 2025 upgraded asymptomatic MV repair to Class I when three of AF/pulmonary hypertension/LA dilation/moderate TR are present. Nothing today shifts that hierarchy.
Tricuspid Valve (TriClip, TTVR)
A brief JACC: CVI communication described transcatheter tricuspid valve stability achieved through annular compression when leaflet capture was incomplete — a mechanistic insight relevant as TTVR indications expand (JACC: Cardiovascular Interventions). A Chinese review reinforced echocardiography's central role in transcatheter tricuspid intervention (Zhonghua Xin Xue Guan Bing Za Zhi). ESC 2025 elevated transcatheter tricuspid treatment to Class IIa (LOE A) based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 predates these trials. Surgical TV repair for symptomatic severe primary TR remains Class I in ESC 2025 (upgraded from IIa), and both guidelines emphasize that patients arrive too late — after RV failure sets in.
Surgical vs. Transcatheter Comparisons
The most consequential piece today is the Medicare bailout analysis. Across 400,862 TAVRs from 2016–2024, surgical bailout occurred in 0.56% overall, dropping from 0.92% in 2016 to 0.40% in 2024 — but 30-day mortality when bailout was needed was 26.3%, with equivalent bailout mortality across low-, intermediate-, and high-volume SAVR hospitals (JACC: Cardiovascular Interventions). [NOTABLE] The accompanying editorials — one titled "Preserve the Heart Team: Surgical Backup Is Not Optional in TAVR" (Cangut et al.), the other on "The Rise of the Solo TAVR Operator" (Hibbert) — bracket the policy debate. As US regulators consider TAVR in hospitals without on-site cardiac surgery, a one-in-four death rate when things go wrong is the number that should anchor the conversation. Both ACC/AHA 2020 and ESC 2025 require Heart Team involvement and available surgical backup for TAVR — today's data reinforce, not challenge, that framework.
Device & Technology
A Japanese series described ascending aortic rotational control with the Navitor Vision delivery system to improve commissural alignment, guided by CT-derived cusp overlap views (Structural Heart). Commissural alignment matters more as lifetime management pushes future TAV-in-TAV planning to the index procedure — a point emphasized in ESC 2025. A case report documented TAVR for pure aortic insufficiency complicated by complete heart block after LVAD implantation (Zhonghua Xin Xue Guan Bing Za Zhi), and a technique note described a kissing balloon rescue for a protruded left main stent during TAVR (JACC: CVI). ESC 2025 added TAVI for AR at Class IIb for inoperable patients — the technology is catching up to the anatomy.
Regulatory & Policy
CMS expanded TAVR reimbursement coverage, widening the Medicare pool for structural heart programs and directly benefiting Edwards Lifesciences (Citeline). Coverage expansion at CMS typically precedes commercial payer alignment, meaning volume tailwinds may extend through 2026–2027 as ESC 2025's lower age threshold and EARLY TAVR data push earlier intervention. Trinity Health in North Dakota reported its first TAVR procedures, illustrating the continued regional expansion of programs into smaller markets (KX News). Read alongside today's Medicare bailout data, expansion into lower-volume settings amplifies the surgical backup question.
Financial Analysis
The CMS TAVR coverage expansion is the day's dominant market signal (ad-hoc-news.de). Options activity in Edwards Lifesciences spiked (MarketBeat) and analysts revisited the investment narrative (Simply Wall Street). The clinical underpinning: expanded coverage aligns US practice with the ESC 2025 shift toward earlier and broader TAVI indication. The stock closed slightly lower on the news, reflecting how much of the expansion was already priced in. Insider selling by Edwards' Daniel Lippis (619 shares at $87.51 post-option exercise) is routine (Kalkine). Edwards' Limerick facility won a global Plant of the Year award, reflecting operational execution amid the growth cycle (Limerick Post).
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $84.74 (-0.92% daily); 6-month +1.41%
- Market Cap: $48.8B | P/E trailing 50.44 / forward 25.09 | Beta 0.85
- 52-Week Range: $72.30 – $96.29
- Analyst Target: $100.96 (26 analysts, buy)
- Next Earnings: Oct 29, 2026 (EPS est $0.74, Rev est $1.68B)
The pure-play structural heart story remains anchored to TAVR volume. Today's CMS coverage expansion is a positive multi-year signal that outweighs the modest daily pullback. Watch Q3 earnings for confirmation of TEER momentum and any early PASCAL-vs-MitraClip commentary.
Medtronic (MDT)
- Price: $93.07 (-0.78% daily); 6-month +7.29%
- Market Cap: $119.0B | P/E trailing 22.92 / forward 14.53 | Beta 0.57
- 52-Week Range: $73.31 – $106.33
- Analyst Target: $104.83 (24 analysts, buy)
- Next Earnings: Nov 17, 2026 (EPS est $1.33, Rev est $9.48B)
The Intrepid TMVR trial (NCT03242642) updated its enrollment plan today to 1,056 patients, keeping Medtronic in the lead for a US TMVR approval pathway. Evolut share and the pacemaker discussion following today's PORTICO data both matter.
Abbott (ABT)
- Price: $101.80 (-1.25% daily); 6-month -6.17%
- Market Cap: $177.3B | P/E trailing 32.94 / forward 16.78 | Beta 0.59
- 52-Week Range: $81.97 – $137.49
- Analyst Target: $120.26 (25 analysts, buy)
- Next Earnings: Oct 14, 2026 (EPS est $1.42, Rev est $12.99B)
MitraClip/TriClip remain the structural heart core. ESC 2025's Class I for TEER in ventricular SMR and Class IIa for transcatheter tricuspid treatment are structural tailwinds that the current share price does not fully reflect.
Boston Scientific (BSX)
- Price: $44.14 (-2.02% daily); 6-month -36.75%
- Market Cap: $64.0B | P/E trailing 17.87 / forward 12.88 | Beta 0.57
- 52-Week Range: $42.20 – $105.65
- Analyst Target: $62.00 (29 analysts, buy)
- Next Earnings: Oct 28, 2026 (EPS est $0.78, Rev est $5.20B)
The 6-month drawdown remains the industry outlier. Watch ACURATE and PASCAL/Sentinel updates at year-end for a re-rating catalyst.
Anteris Technologies (AVR.AX)
- Price: A$12.00 (+3.99% daily); 6-month +41.18%
- Market Cap: $1.2B | Forward P/E -5.54
- 52-Week Range: $5.20 – $15.47
The DurAVR small-cap continues to run on early clinical enthusiasm. Pivotal enrollment progress will define whether current levels hold.
The bigger picture: CMS coverage expansion, ESC 2025 pushing TAVI eligibility earlier, and EARLY TAVR moving asymptomatic patients into the intervention pool all favor procedural volume. Today's Medicare bailout data and the PORTICO pacemaker signal are the counterweights — reminders that safety and durability, not volume, will define winners over the next five years.
Clinical Trial Updates
Mitral Replacement
- [LANDMARK] NCT03242642 — APOLLO (Intrepid TMVR): Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System. RECRUITING, N=1,056, Medtronic Cardiovascular. Updated Sep 15, 2026. Enrollment increase reinforces Intrepid's position as the most advanced US TMVR pivotal — a critical read on whether TMVR can meaningfully expand beyond TEER-ineligible anatomy.
The next inflection points: Edwards' Oct 29 earnings for the first quantitative read on the CMS coverage expansion, and TCT 2026 for anticipated updates on TRISCEND II, RESHAPE-HF2 subgroups, and continued 5-year data streams from low-risk TAVR cohorts. The bicuspid TAVR debate will not resolve until randomized data land — but today the empirical gap narrowed.